With PROIBS® turning 10 years old in a time where the world is still facing an unprecedented global health crisis, it is important for us to reflect on the past, and more importantly, to focus on the future. 

Our growth over the years has been a cumulative outcome of the hard work and non-stop efforts of every individual associated with us. Our core values, strong focus on R&D and our commitment to gut health remain the guiding principles for everything we do and we are anticipating a positive future and a long-term market for PROIBS® on the European market. We are excited to see where we stand in the next 10 years with PROIBS® on the world market. Here’s to another brilliant 10 years!

Tobias Kisker

CEO, Calmino Group AB

Looking back at a eventful decade

Since 2007, Calmino Group’s focus has been on products aimed to improve human gut health. Today, our best-selling product, PROIBS® turns 10 years old. In 2010, PROIBS® first went on sale in Sweden and fast forward a decade later, Calmino Group has sold more than 15 million PROIBS® sachetsThe product is today one of the most popular IBS products on the Swedish pharmacy market and is recommended by health care professionals, pharmacists and consumers.

Happy birthday to PROIBS®! To mark the occasion, today we’ll take a brief look at PROIBS® history throughout the years.

2010: PROIBS® was developed and launched by Calmino group AB in 2010 after a randomized double-blind placebo study was completed at Sahlgrenska University Hospital.

Late 2010: PROIBS® launched in Sweden as an FSMP, Food for Special Medical Purposes.

2013: Signed first distribution agreement with Nordic Drugs, Sweden.

2016: Calmino group AB started sales on the international market. Austria is first out early 2016 and South Africa followed in June. At the same time, Calmino immersed in more research together with Chalmers and the Sahlgrenska Academy (Gothenburg University) and collaborated with more key players, internationally.

Late 2016: “Initially, we were mainly focused on the European market but we received a lot of demand from other countries and we realised, our scope was bigger – there was a large portion of the world interested in PROIBS®. After two important scientific publications, the interest from different countries has increased even more”, says Tobias Kisker, CEO of Calmino.

2017: PROIBS® international export grew and the first few countries include, Austria, South Africa, Iraq, Turkey and Japan.

2019: After many successful years in the pharmacy market,  recommended by health care professionals, pharmacists and consumers, in 2019, the product was certified as a Class IIb certified medical device product for the treatment of symptoms related to IBS such as abdominal pain, bloating and changes in bowel movement (diarrhoea and/or constipation).

2020: PROIBS® became as a Class IIb certified medical device product in Europe.

Late 2020: Calmino announces the launch of PROIBS® in Greece. (Link to News Article)

Early 2021: PROIBS® television commercials were aired successfully in several big television channels in Greece for several weeks, thanks to a great product launch campaign run by Pharmaserve Lilly. (Link to News Article)

Calmino Group team today.

It’s incredible to think how quickly the past 10 years have flown by. Every step of our journey has brought new challenges and memorable experiences. Looking forward to the future! 

We are looking for distributors worldwide.

Looking for new products to present in your market? Can you help us enter a new market? Our goal is to maintain constant growth based on expansion into new markets and an improved presence in current markets. Should you see an opportunity for our co-operation, please do not hesitate to contact us! Grow your business by becoming our official business partner! 

For all regions, including international, please e-mail us: info@calmino.com